Recombinant Proteins

news September 20 2019

 

Sino Biological Inc. has over 10 years’ experience of recombinant protein research and development, covering most hot research areas, such as immune checkpoints, antibody drug targets, CAR-T cell therapy targets, Fc receptors, influenza viral proteins and cytokines.
Possessing high purity and validated bioactivity, Sino Biological recombinant proteins can support your scientific research from biopharmaceutical, protein structure, protein function, cell therapy to tool enzymes.

Featured Recombinant Proteins

  • Immune Checkpoint Proteins
  • CAR-T Cell Therapy Targets
  • Antibody Therapeutic Targets
  • Cytokine & Growth Factor
  • Fc Receptors
  • Biotinylated Proteins

A Global Leader in Recombinant Protein R & D

Advanced Technology Platforms

  • Five expression systems to support production
  • Protein from multiple species to support animal models and drug development
  • 70 qutomatic bioreactor
  • 2L-2000L bioreactors to ensure high throughout manufacture
  • GMP-level workshop
  • Milligram level protein production

Strict quality control system

  • Over 1000 methods for activity assay
  • State-of-the-art analytical equipment set to ensure validated bioactivity
  • N-terminal amino acid sequence analysis
  • Better stability to ensure repeated experiments
  • Qualified raw materials to ensure animal free

Premium Recombinant Protein Products

  • >85% expressed by eukaryotic cell, close to natural structure
  • Validated bioactivity
  • Lower endotoxin: <0.1 EU per μg by LAL
  • High purity: >95% by SDS-PAGE or HPLC
  • Carrier Free: dissolved in PBS, without BSA

Recombinant protein of high purity

Fig .1 The purity of human TNFα protein (Cat. No. GMP-10602-HNAE) was >97% determined by SEC-HPLC and >96% determined by SDS-PAGE

Recombinant protein with high bioactivity

Fig .2 The comparison of VEGF165 bioactivity from Sino Biological (EC50=1.4 ng/ml) and another brand (EC50=4 ng/ml) in cell proliferation assays using HUVEC.

Recombinant protein with high binding activity

Fig .3 The PD-1 (Cat. No. 10377-H03H) binding ability to PD-L2 was measured in a functional ELISA. ED50=0.94 μg/ml.

Custom Recombinant Protein Production

  • E.coli expression service
  • HEK293/CHO transient expression service
  • Yeast expression service
  • Baculovirus-insect expression service
  • CHO/HEK293 stable cell line development

Recombinant Protein Production Service Description

Sino offer one-stop services for recombinant protein production using our advanced protein expression platform technologies. Their full services include protein gene synthesis, protein codon optimization, protein expression vector design, large scale cell culture and fermentation, protein purification, and protein quality control testing. They offer significant cost saving advantages and record speed in protein expression and bulk production. They also have extensive experiences and expertise in handling various types of recombinant protein purification projects, with or without purification tags.

Sino Biological has in-house capacity to support 1000-2000 recombinant protein development and bulk production per year. They can do rapid protein expression and purification process development and conduct process scaleup studies. They can meet protein production requirements for both high-throughput and large scale bulk productions. In the last couple of years, they have successfully produced over 6000 recombinant protein bulks (in the range of milligram to gram purified proteins). The unprecedented capacity can be utilized by our customers worldwide to accelerate their basic research, structural biology, product discovery, and product development.

They are committed to becoming the cost-effective centralized lab for recombinant protein and monoclonal antibody bulk production to serve the life science community and biotech industry worldwide. They strive to change the way the life science community and industry generating and sourcing their proteins.